ArticleInflammation2025
NLRP3-inflammasome Related Genes as Emerging Biomarkers and Therapeutic Targets in Psoriasis.
Article in Inflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Inflammasome-derived biomarkers in wound healing: linking tissue repair, chronic inflammation, fibrosis, and precision therapeutics.Molecular biology reports · 2026Review
- Skin Application of Inflammasome Inhibitor MCC950 Prevents Psoriasis-like Cutaneous Manifestations and Associated Systemic Inflammation.Inflammation · 2026Article
- Review
- Dimethyl fumarate as a versatile therapeutic agent: molecular mechanisms and potential clinical applications.Molecular biology reports · 2026Review
- Article
- Identification and validation of a nomogram for psoriasis diagnosis: a novel biomarker combination with stable high expression in the early stage.Frontiers in medicine · 2026Article
- Mechanisms and active components ofFrontiers in immunology · 2026Article
- Life's Crucial 9 and psoriasis: a mediation analysis of systemic inflammation response index using NHANES cohort data.Frontiers in immunology · 2025Article
- Resveratrol in Dermatological Therapy: A Critical Review of Mechanisms, Delivery Innovations, and Clinical Frontiers.Clinical, cosmetic and investigational dermatology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The NLRP3 inflammasome is closely associated with inflammatory diseases, including psoriasis. Objective diagnostic biomarkers and alternative therapies for psoriasis remain limited. We aimed to identify reliable biomarkers for the diagnosis of psoriasis and investigate potential therapy strategies. Machine learning methods were performed in over 1000 skin samples from public transcriptome database to identify NLRP3 inflammasome-related biomarkers. Multivariate Cox regression analysis was used to establish the biomarker-based diagnostic model. TNF-induced HaCaT cell model was used to evaluate biomarker-related inflammatory changes. Biomarker-targeting drugs was predicted with NetworkAnalyst database and validated in imiquimod (IMQ)-induced mouse model. Elevated level of four NLRP3 inflammasome-related biomarkers, including NLRP3, ASC, TXNIP and CASP-1, were identified from the public psoriasis transcriptome samples and validated in our local psoriasis skin biopsies. The biomarker-based diagnostic model was developed from training dataset and validation dataset, which both showed significant diagnostic value for psoriasis. Knocking down one of these genes in vitro showed reduced inflammatory factors, reduced cell apoptosis and improved cell viability. Furthermore, Predictive biomarker-targeting therapeutics, including resveratrol and JQ-1, demonstrated effective alleviation of psoriasis severity and reduced inflammation in IMQ-induced psoriasis mice. Combinational evaluation of NLRP3, ASC, TXNIP and CASP-1 may constitute a novel diagnostic approach for psoriasis. Targeting these proteins provide more options for psoriasis therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.